[HTML][HTML] Cancer immune evasion through loss of MHC class I antigen presentation
K Dhatchinamoorthy, JD Colbert, KL Rock - Frontiers in immunology, 2021 - frontiersin.org
Major histocompatibility class I (MHC I) molecules bind peptides derived from a cell's
expressed genes and then transport and display this antigenic information on the cell …
expressed genes and then transport and display this antigenic information on the cell …
[HTML][HTML] Cancer immunotherapies: from efficacy to resistance mechanisms–not only checkpoint matters
S Wang, K Xie, T Liu - Frontiers in immunology, 2021 - frontiersin.org
The immunotherapeutic treatment of various cancers with an increasing number of immune
checkpoint inhibitors (ICIs) has profoundly improved the clinical management of advanced …
checkpoint inhibitors (ICIs) has profoundly improved the clinical management of advanced …
[HTML][HTML] Proteomic analysis of archival breast cancer clinical specimens identifies biological subtypes with distinct survival outcomes
Despite advances in genomic classification of breast cancer, current clinical tests and
treatment decisions are commonly based on protein level information. Formalin-fixed …
treatment decisions are commonly based on protein level information. Formalin-fixed …
[HTML][HTML] The current landscape of NKT cell immunotherapy and the hills ahead
Simple Summary Natural killer T (NKT) cells are a subset of lipid-reactive T cells that
enhance anti-tumor immunity. While preclinical studies have shown NKT cell …
enhance anti-tumor immunity. While preclinical studies have shown NKT cell …
[HTML][HTML] MAL2 drives immune evasion in breast cancer by suppressing tumor antigen presentation
Immune evasion is a pivotal event in tumor progression. To eliminate human cancer cells,
current immune checkpoint therapy is set to boost CD8+ T cell–mediated cytotoxicity …
current immune checkpoint therapy is set to boost CD8+ T cell–mediated cytotoxicity …
Sensitizing cancer cells to immune checkpoint inhibitors by microbiota-mediated upregulation of HLA class I
V Ferrari, AL Cascio, A Melacarne, N Tanasković… - Cancer Cell, 2023 - cell.com
Recent data have shown that gut microbiota has a major impact on the clinical response to
immune checkpoint inhibitors (ICIs) in the context of solid tumors. ICI-based therapy acts by …
immune checkpoint inhibitors (ICIs) in the context of solid tumors. ICI-based therapy acts by …
Pharmacological disruption of the MTDH–SND1 complex enhances tumor antigen presentation and synergizes with anti-PD-1 therapy in metastatic breast cancer
Despite increased overall survival rates, curative options for metastatic breast cancer remain
limited. We have previously shown that metadherin (MTDH) is frequently overexpressed in …
limited. We have previously shown that metadherin (MTDH) is frequently overexpressed in …
Understanding patterns of brain metastasis in triple-negative breast cancer and exploring potential therapeutic targets
Y Lv, X Ma, Y Du, J Feng - OncoTargets and therapy, 2021 - Taylor & Francis
Triple-negative breast cancer (TNBC) is a highly malignant subtype of breast cancer. High
invasiveness and heterogeneity, as well as a lack of drug targets, are the main factors …
invasiveness and heterogeneity, as well as a lack of drug targets, are the main factors …
[HTML][HTML] Natural killer T cell immunotherapy combined with oncolytic vesicular stomatitis virus or reovirus treatments differentially increases survival in mouse models …
S Gebremeskel, A Nelson, B Walker… - … for immunotherapy of …, 2021 - ncbi.nlm.nih.gov
Background Oncolytic viruses reduce tumor burden in animal models and have generated
promising results in clinical trials. However, it is likely that oncolytic viruses will be more …
promising results in clinical trials. However, it is likely that oncolytic viruses will be more …
CDK4/6 inhibitors induce breast cancer senescence with enhanced anti‐tumor immunogenic properties compared with DNA‐damaging agents
Since therapy‐induced senescence (TIS) can either support or inhibit cancer progression,
identifying which types of chemotherapeutic agents can produce the strongest anti‐tumor …
identifying which types of chemotherapeutic agents can produce the strongest anti‐tumor …